IP Library Granted Patent US 9,815,826
Granted Patent B2
US 9,815,826 · App. 15/328,146 · Granted Nov 14, 2017

Crystal of azole benzene derivative

Inventors: Asahi Kawana (Tokyo, JP); Yuki Miyazawa (Tokyo, JP)
Assignee: Teijin Pharma Limited
C07D417/10C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,826
App. No.
15/328,146
Granted
Nov 14, 2017
Kind
B2
Abstract

There are provided crystals of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid which is useful as a therapeutic agent or prophylactic agent for gout, hyperuricemia and the like.

Claims (4)

1. A crystal form A of 2-[4-(2,2-dimethylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid, wherein the crystal has characteristic peaks at diffraction angles of 2θ=7.2°, 11.3°, 15.9°, 17.9°, 20.8°, 22.3°, 23.1°, 23.8°, 24.3° and 28.6° in its powder X-ray diffraction spectrum.

2. The crystal according to claim 1 , wherein its powder X-ray diffraction spectrum has a pattern shown in FIG. 1 .

3. The crystal according to claim 1 , wherein its exothermic peak in thermogravimetry/differential thermal analysis is at 232° C.

4. A pharmaceutical composition comprising the crystal according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2018
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 047322/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2017
From: KAWANA, ASAHI; MIYAZAWA, YUKI
To: TEIJIN PHARMA LIMITED
Reel/Frame 041048/0959 →
Priority Claims (1)
JP 2014-155031 · Jul 30, 2014 · national
Continuity (1)
Related Publication 20170210735A1 · Jul 27, 2017